The →pp→pK+Λ reaction has been measured with the COSY-TOF detector at a beam momentum of 2.7GeV/c. The polarized proton beam enables the measurement of the beam analyzing power by the asymmetry of the produced kaon (AKN). This observable allows the pΛ spin triplet scattering length to be extracted for the first time model independently from the final state interaction in the reaction. The obtained value is at=(−2.55+0.72−1.39stat.±0.6syst.±0.3theo.)fm. This value is compatible with theoretical predictions and results from model-dependent analyses.Received 4 August 2016Revised 13 January 2017DOI:https://doi.org/10.1103/PhysRevC.95.034001©2017 American Physical SocietyPhysics Subject Headings (PhySH)Research AreasHadron-hadron interactionsNucleon-nucleon interactionsPolarization phenomenaPhysical SystemsHyperonsParticles & FieldsNuclear Physics

1 Institut für Kernphysik, Forschungszentrum Jülich, 52428 Jülich, Germany 2 Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany 3 Physikalisches Institut der Universität Tübingen, Auf der Morgenstelle 14, 72076 Tübingen, Germany 4 Kepler Center for Astro and Particle Physics, University of Tübingen, Auf der Morgenstelle 14, 72076 Tübingen, Germany 5 Institut for Advanced Simulation and Jülich Center for Hadron Physics, Forschungszentrum Jülich, 52428 Jülich, Germany 6 Institute of Physics, Jagellonian University, PL-30-348 Cracow, Poland 7 Jülich Aachen Research Alliance, Forces and Matter Experiments (JARA-FAME), Germany 8 Experimentalphysik I, Ruhr-Universität Bochum, 44780 Bochum, Germany 9 Corporate Development, Forschungszentrum Jülich, 52428 Jülich, Germany 10 Zentralinstitut für Engineering, Elektronik and Analytik, Forschungszentrum Jülich, 52428 Jülich, Germany (Dated: March 29, 2017)

The (cid:2) pp → pK + (cid:2) reaction has been measured with the COSY-TOF detector at a beam momentum of 2 . 7GeV /c . The polarized proton beam enables the measurement of the beam analyzing power by the asymmetry of the produced kaon ( A KN ). This observable allows the p(cid:2) spin triplet scattering length to be extracted for the first time model independently from the final state interaction in the reaction. The obtained value is a t = ( − 2 . 55 + 0 . 72 − 1 . 39stat . ± 0 . 6 syst . ± 0 . 3 theo . )fm. This value is compatible with theoretical predictions and results from model-dependent analyses.

The pp -> pK(+) Lambda reaction has been measured with the COSY-TOF detector at a beam momentum of 2.7 GeV/c. The polarized proton beam enables the measurement of the beam analyzing power by the asymmetry of the produced kaon (A(N)(K)). This observable allows the p Delta spin triplet scattering length to be extracted for the first time model independently from the final state interaction in the reaction. The obtained value is a(t) = (-2.55(-1.39stat.)(+0.72) +/- 0.6(syst.) +/- 0.3(theo.))fm. This value is compatible with theoretical predictions and results from model-dependent analyses.

The Lambda polarization, the analyzing power, and the Lambda spin transfer coefficient of the reaction pp -> p K+ Lambda were measured at beam momenta of 2.70 GeV/c and 2.95 GeV/c, corresponding to excess energies of 122 MeV and 204 MeV. While the analyzing power and the spin transfer coefficient do not change significantly with the excess energy, the Lambda polarization varies strongly and changes its sign. As this is the first measurement of polarization observables below an excess energy of 200 MeV, the change of the sign of the Lambda polarization was not observed before. The high statistics of the data (~200 k events for each momentum) enables detailed studies of the dependence of the Lambda polarization and the analyzing power on the center of mass momentum of the particles. The results of the spin transfer coefficient are in qualitative agreement with the DISTO experiment. The Lambda polarization data of 2.95 GeV/c are only conform with the DISTO experiment, while both the 2.70 GeV/c and 2.95 GeV/c data differ strongly from all previous measurements, whether exclusive or inclusive.

A new high-precision measurement of the reaction \(pp\rightarrow pK^{+}\Lambda\) at a beam momentum of 2.95 GeV/c with more than 200 000 analyzed events allows a detailed analysis of differential observables and their inter-dependencies. Correlations of the angular distributions with momenta are examined. The invariant mass distributions are compared for different regions in the Dalitz plots. The cusp structure at the \(N\Sigma\) threshold is described with the Flatté formalism and its variation in the Dalitz plot is analyzed.

The p⃗p → pK^+Λ reaction has been measured with the COSY-TOF detector at a beam momentum of 2.7 GeV/c. The polarized proton beam enables the measurement of the beam analyzing power by the asymmetry of the produced kaon (A_N^K). This observable allows the pΛ spin triplet scattering length to be extracted for the first time model independently from the final-state interaction in the reaction. The obtained value is a_t = (-2.55 ^+0.72_-1.39_stat.± 0.6_syst.± 0.3_theo.)fm. This value is compatible with theoretical predictions and results from model-dependent analyses.

Purpose: Heart failure (HF), vascular disease and atrial fibrillation (AF) are all pathophysiological related and understanding antithrombotic therapy is crucial. Our aim was to investigate the impact of AF and antithrombotic therapy on prognosis in HF patients with co-existing vascular disease. Methods: In a nationwide cohort of patients hospitalized with HF and vascular disease (coronary artery disease and peripheral arterial disease), AF status was categorized as prevalent, incident and no AF. Patients were followed from 1997 to 2009 and risks of thromboembolism (TE) and serious bleeding were assessed by Cox regression models with antithrombotic therapy (single antiplatelet, vitamin K antagonist (VKA) or both) and AF as time-dependent variables. Crude rates are events per 100 person-years. Results: A total of 37,464 patients were included (mean age 74.5 [SD 10.7] years, 36.3% females) and mean follow-up of was 3.0 years. Of these, 7,804 (20.7%) had prevalent AF while incident AF occurred in 6,432 (17.2%). Impact of AF and antithrombotic therapy on TE and bleeding risk is shown below. Relative to VKA therapy, consistent increased risk of TE was present in AF patients on single antiplatelet therapy with no decrease in risk when combining antiplatelet with VKA therapy. In patients without AF, no difference in TE risk was found between antithrombotic regimens. Bleeding risk was significantly raised in all patients on dual therapy with antiplatelet and VKA. Impact of AF and antithrombotic therapy Conclusions: In patients with co-existing HF and vascular disease, AF has an adverse effect on thromboembolism and bleeding. Adding antiplatelet therapy on top of VKA therapy is not associated with additional benefit on thromboembolic risk, but notably increased risk of bleeding.

The possibility to determine the pLambda scattering length from the final-state interaction in the reaction pp->pKLambda is investigated experimentally. From a transversely polarized measurement, the K analyzing power (A_N) which, in principle, allows one to extract the spin triplet scattering length is studied. An unexpected energy dependence of the forward/backward symmetric part of A_N is found. The influence of N*-resonances on the pLambda invariant mass spectrum is investigated by exploiting the large acceptance for the process pp->pKLambda->pKppi and is found to be the main source of uncertainty for determining the pLambda scattering length.

Purpose: The optimal antithrombotic treatment strategy is unresolved in patients with multiple indications. We investigated the risk of thrombosis and bleeding according to multiple antithrombotic treatment regimes in atrial fibrillation (AF) patients after myocardial infarction (MI) or coronary intervention (PCI). Methods: A total of 12,165 AF patients hospitalized with MI and/or undergoing PCI between 2001-2009 were identified by nationwide registries (60.7% males, mean age 75.6 years). Risk of MI or coronary death, ischemic stroke, bleeding and all-cause death according to antithrombotic treatment regimen was estimated by Cox regression models. Results: Within one year, MI or coronary death, ischemic stroke, and bleeding events occurred in 2,255 (18.5%), 680 (5.6%), and 769 (6.3%) patients, respectively. Crude rates for MI or coronary death were 16.2, 9.6, and 17.7 events per 100 person-years for triple therapy (oral anticoagulation (OAC) + aspirin + clopidogrel), OAC + clopidogrel and OAC + aspirin, respectively. The corresponding crude rates for ischemic stroke were 4.1, 2.8 and 5.6, while for bleeding 14.3, 10.9 and 9.7 events per 100 person-years. Crude rates for triple therapy (8.9 per 100 person-years) and OAC plus clopidogrel (7.1 per 100 person-years) were lower than for OAC plus aspirin. Adjusted HRs are shown in the Figure. ![Figure][1] Effectiveness and safety Conclusion: In a nationwide cohort of AF patients with indication for triple therapy after MI/PCI, the combination of OAC and clopidogrel was equal or better on both effectiveness and safety outcomes compared to other multiple antithrombotic treatment regimes including recommended triple therapy. [1]: pending:yes

In a double-blind randomised group comparative trial the adverse effects of the β-blockers acebutolol and metoprolol were compared in patients with arterial hypertension. The patients were asked before and during treatment about a number of complaints/symptoms, known to be common adverse reactions to β-blockers. A total of 215 patients were randomised, and 82 in each group completed 16 weeks’ treatment. No statistically significant differences were found in the reduction in blood pressure and heart rate, and confidence limits excluded major differences. After 4 weeks the heart rate was reduced more in the metoprolol group than in the acebutolol group. Before and after 16 weeks’ treatment no differences were found in either the number of patients with complaints/symptoms or in the severity of these complaints. Both parameters were reduced evenly during the study. Patients receiving metoprolol complained more often of palpitations 4 weeks after the start of treatment. Our results indicate that the choice between acebutolol and metoprolol should not be based on therapeutic efficacy or on adverse effects.

Syncope is a common cause for hospitalization and may be a related to comorbid illnesses and concurrent medications. The main objective of this study was to determine the incidence, comorbidity and pharmacotherapy in a nationwide cohort of patients transferred to hospital with syncope. The study